A Melbourne-based medical biotech, backed by RMIT University ... iStock Street Talk understands NEXSEN is seeking to raise $2 ...
Biotech HaemaLogiX – which counts former health minister Greg Hunt as a director – is preparing a 2025 ASX listing, as it ...
HanX Biopharmaceuticals is planning a Hong Kong listing to fund the phase 2 trial of its lead solid tumor drug. | HanX ...
Why Is Legend Biotech Corp. (LEGN) Among the Best Up and Coming Stocks to Buy According to Analysts?
With an anticipated strong IPO market in 2025 ... benchmark by 150 percentage points (see more details here). Legend Biotech Corp. (NASDAQ:LEGN) is a clinical-stage biopharmaceutical company ...
Why Is Legend Biotech Corp. (LEGN) Among the Best Up and Coming Stocks to Buy According to Analysts?
In this article, we are going to take a look at where Legend Biotech Corp. (NASDAQ ... companies that have been hesitant to pursue IPOs in 2025, capitalizing on the positive market reaction ...
Biotech investors will ... HaemaLogiX’s preliminary view is that it will raise $50m as part of next year’s IPO. HaemaLogiX, in its current form, has so far raised $24.1m.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback